• AstraZeneca plc, of London, said subanalysis data from its VOYAGER study suggested that achieving an LDL-C goal of less than 70 mg/dL or a greater than 50 percent reduction in LDL-C levels in patients at high risk requires aggressive statin therapy. Results showed that a significantly greater percentage of patients achieved that goal with Crestor (rosuvastatin) than with equal or double doses of Lipitor (atorvastatin, Pfizer) or Zocor (simvastatin, Merck & Co. Inc.) Data were presented at the International Symposium on Atherosclerosis in Sydney, Australia.

• CSL Behring, of Charlotte, N.C., said the first patient was enrolled in the PATH (Polyneuropathy And Treatment with Hezentra) study to evaluate the safety and tolerability of two different doses of subcutaneous immunoglobulin compared to placebo in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). The study will measure the proportion of patients who experience a relapse in their CIDP over a period of 52 weeks.